Cutaneous angiosarcoma: update on biology and latest treatment

Area of Science:

• Oncology
• Dermatology
• Genetics

Background:

• Cutaneous angiosarcoma (cAS) is a rare vascular tumor.
• Genomic alterations in cAS are diverse, with frequent mutations in the MAPK pathway.

Purpose of the Study:

• To provide an updated review on the biology and clinical management of cAS.
• To highlight recent findings and future research directions.

Main Methods:

• Review of recent scientific literature on cAS.
• Analysis of genomic alterations and potential therapeutic targets.
• Evaluation of current and emerging treatment strategies.

Main Results:

• Identified potential biomarkers and therapeutic targets including survivin, HSP90, FOXM1, miR-497-5p, KCa3.1, and miR210.
• Standard treatment involves surgery and radiotherapy; paclitaxel is recommended for advanced cAS.
• Pazopanib and bevacizumab show efficacy, while eribulin mesylate and trabectedin are under investigation.
• The role of the immune system in cAS is increasingly recognized.

Conclusions:

• Despite molecular advances, clinical translation for cAS remains limited.
• Future research should prioritize drug development for molecular targets, cAS-specific clinical trials, and immunotherapy.